196 related articles for article (PubMed ID: 32193450)
1. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
[TBL] [Abstract][Full Text] [Related]
2. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
3. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
4. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
5. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
[TBL] [Abstract][Full Text] [Related]
6. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
Front Immunol; 2020; 11():364. PubMed ID: 32194568
[TBL] [Abstract][Full Text] [Related]
8. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
[TBL] [Abstract][Full Text] [Related]
9. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
[TBL] [Abstract][Full Text] [Related]
10. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
11. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
13. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
Adv Anat Pathol; 2017 Nov; 24(6):311-335. PubMed ID: 28777143
[TBL] [Abstract][Full Text] [Related]
14. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600
Klein S; Mauch C; Brinker K; Noh KW; Knez S; Büttner R; Quaas A; Helbig D
Sci Rep; 2021 Jan; 11(1):1834. PubMed ID: 33469107
[TBL] [Abstract][Full Text] [Related]
15. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
16. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
19. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]